Skip to main content
. 2023 Nov 30;64:34. doi: 10.1186/s40529-023-00406-8

Table 4.

Anti-angiogenic activity of isolated compounds in human EPCs

compound IC50 (µM) a
1 > 50
2 > 50
3 > 50
4 > 50
5 5.6 ± 0.1
6 > 50
7 > 50
8 4.6 ± 0.1
9 8.1 ± 0.4
10 0.8 ± 0.3
11 5.2 ± 0.3
12 2.9 ± 0.3
13 > 50
14 > 50
Sorafenib b 4.8 ± 0.3

aEPCs were treated with the indicated compounds for 48 h. Anti-angiogenic effects were evaluated in a cell growth assay (n = 3). Data are displayed as the mean ± SEM

bPositive control used in this study